中晚期鼻咽癌放射治疗联合同步或诱导化疗的临床观察  

Clinical study on short-term response of two kinds of associated concomitant radio-chemotherapy for advanced nasopharyngeal carcinoma

作　　者：樊锐太[1] 郭艳娜[1] 王敬敏[1] 张洪志[1] 顾浩[1] 

机构地区：[1]郑州大学第一附属医院放疗科,河南郑州450052

出　　处：《中华肿瘤防治杂志》2008年第24期1885-1886,1897,共3页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:探讨同步放化疗与诱导化疗治疗中晚期鼻咽癌的近期疗效及毒副反应。方法:将48例患者依据临床资料相似、具有可比性原则分为同步组(A)26例和诱导组(B)22例。两组放疗方案相同,原发灶放疗方案为双侧面颈联合野常规分割放疗40Gy后光子刀加量,DT(70～76)Gy/(5～7)周;颈部淋巴结行常规分割放疗后局部加量。两组应用DF化疗方案(DDP20mg/m2,静脉滴入,d1～d5;5-FU500mg/m2,静脉滴入,d1～d5)。A组放疗的前、中、后期各行1个周期化疗;B组放疗前行3个周期化疗。结果:A、B两组原发灶有效率分别为92.3%(24/26)和82.0%(18/22),完全缓解率分别为73.0%(19/26)和68.1%(15/22),两组原发灶近期疗效差异有统计学意义,P=0.036;A、B两组颈部淋巴结有效率均为100%,完全缓解率分别为100%(20/20)和85.0%(17/20),两组颈部淋巴结疗效差异无统计学意义,P=0.317。毒副反应中,两组骨髓抑制及胃肠道反应差异有统计学意义,P值分别为0.024和0.019;口腔黏膜反应差异无统计学意义,P=0.339。结论:同步放化疗近期疗效优于诱导放化疗,但同步放化疗毒副反应大于诱导放化疗。OBJECTIVE: To study the difference of short-term response between concurrent radio-chemotherapy and neoadjuvant chemtherapy in the treatment of advanced nasopharyngeal carcinoma.METHODS:Forty-eight patients with advanced nasopharyngeal carcinoma were randomly divided into two groups to receive concurrent chem-oradiotherapy(Group A,n=26) and neoadjuvant chem-oradiotherapy(Group B,n=22) respectively.Primarily tumors in the radiotherapy program were treated with two-side suface-neck associated campus conventio...

关 键 词：鼻咽肿瘤/放射疗法 鼻咽肿瘤/药物疗法 药物疗法 联合 

分 类 号：R739.63[医药卫生—肿瘤]